Comparative Pharmacology
Head-to-head clinical analysis: DYMELOR versus GLUCOTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYMELOR versus GLUCOTROL.
DYMELOR vs GLUCOTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfonylurea that stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels, leading to membrane depolarization and calcium influx.
Stimulates insulin secretion from pancreatic beta cells by binding to sulfonylurea receptor 1 (SUR1) on ATP-sensitive potassium channels, causing depolarization and calcium influx. Also may increase peripheral insulin sensitivity.
Initial dose: 250 mg orally once daily with breakfast; maintenance dose: 250-500 mg orally once daily; maximum dose: 1000 mg per day.
Initial dose 5 mg orally once daily, increased by 2.5-5 mg increments weekly based on glycemic response; maximum 20 mg daily as single or divided doses (for doses >15 mg, administer in divided doses).
None Documented
None Documented
Terminal elimination half-life is 6-10 hours; clinically significant as it supports once-daily dosing.
Terminal elimination half-life: 2-4 hours (mean 3.4 hours) in normal subjects; extended up to 8-12 hours in elderly or hepatic impairment due to reduced clearance.
Primarily renal excretion of metabolites and unchanged drug (approximately 70-80%), with biliary/fecal excretion accounting for 10-20%.
Primarily renal: ~80% as metabolites (mainly 4-trans-hydroxyglipizide and 3-cis-hydroxyglipizide) and ~10% unchanged; fecal: ~10%.
Category C
Category C
Sulfonylurea Antidiabetic
Sulfonylurea Antidiabetic